Figure 2From: Safety and tolerability of once-daily umeclidinium/vilanterol 125/25 mcg and umeclidinium 125 mcg in patients with chronic obstructive pulmonary disease: results from a 52-week, randomized, double-blind, placebo-controlled studyAEs in the ITT population. *Includes on-treatment and post-treatment AEs. AE, adverse event; ITT, intent-to-treat; SAE, serious AE; UMEC, umeclidinium; VI, vilanterol. Patient numbers are indicated above bars.Back to article page